This is a preview of subscription content, log in via an institution to check access.
Notes
2020 US dollars
Reference
Patel KK, et al. Cost-Effectiveness of First-Line Versus Second-Line Use of Daratumumab in Older, Transplant-Ineligible Patients With Multiple Myeloma. Journal of Clinical Oncology : 7 Jan 2021. Available from: URL: http://doi.org/10.1200/JCO.20.01849
Rights and permissions
About this article
Cite this article
First-line daratumumab not cost effective for transplant-ineligible MM. PharmacoEcon Outcomes News 870, 8 (2021). https://doi.org/10.1007/s40274-021-7411-y
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-021-7411-y